ABSI Stock — Absci Corp

Up next

Next earnings call

Mar 23, 2027 Est · unconfirmed · in 18 wks

Q2 2026 earnings call transcript

call held Aug 11, 2026

Play latest call

Latest documents

2026

Nov 12

Registration statement S-3ASR

Registration statement AI summary on its way

Nov 12

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly report for FY2026 Q3 AI summary on its way

Revenue $304K ▼ 19.6% Net loss $33.3M Diluted EPS -$0.19

Nov 12

Current report 8-K

Financial results, Other events AI summary on its way

Sep 16

Investor event

Morgan Stanley 24th Annual Global Healthcare Conference AI summary on its way

Sep 15

Investor event

H.C. Wainwright 28th Annual Global Investment Conference AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$1.49M

Trailing 12 months

Net income (TTM)

−$125.67M

Trailing 12 months

Revenue growth YoY

-19.6%

Year over year

Operating margin

-8,812.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$173.67M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+19.5%

Year over year · more shares

Price change (1Y)

+220.1%

Trailing year

Short interest

20.7%

Latest settlement · 9.1 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▲96.7% $665,000 −$28.98M '24 Q4* ▲31.3% $1.18M −$26.35M '25 Q1 ▼53.3% $593,000 −$30.57M '25 Q2 ▼77.8% $378,000 −$28.71M '25 Q3 ▼2.3% $650,000 −$29.56M '25 Q4* ▼81.8% $215,000 −$29.60M '26 Q1 ▼46.4% $318,000 −$33.21M '26 Q2 LATEST ▼19.6% $304,000 −$33.30M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 11, 2026

Q2 FY26

TL;DR. Absci reported positive interim Phase 1 ABS-201 data supporting a potential two-to-three injection dosing regimen, completed a $100 million financing including a $40 million Eli Lilly strategic investment, extended its cash runway into the second half of 2028, and announced the upcoming initiation of an ABS-201 Phase 2 endometriosis trial in Q4 2026.

Bullish

+ Positive interim Phase 1 ABS-201 data suggest favorable safety and a half-life of at least 65 days, supporting a potential two-to-three injection regimen over six months.
+ Absci completed a $100 million underwritten offering, including a $40 million strategic equity investment from Eli Lilly.
+ Cash runway extended into the second half of 2028 following the financing.
+ Eli Lilly joined Absci's Endometriosis Advisory Board as part of the new partnership.
+ Absci anticipates initiating a Phase 2 trial of ABS-201 in endometriosis in Q4 2026, with potential proof-of-concept data in 2H 2027.
+ Modeling supports greater than 90% sustained prolactin receptor occupancy with two-to-three doses over six months, which management believes is a key driver of efficacy.

Bearish

− Net loss widened to $33.2 million in Q2 2026 from $30.6 million in Q2 2025.
− R&D expenses increased to $22.6 million from $20.5 million year-over-year.
− Revenue declined to $0.3 million from $0.6 million year-over-year.
− Durability of ABS-201 efficacy will not be demonstrated at the 13-week or 26-week interim readouts.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +24%

above

Price vs 50-day avg −12%

below

RSI (14) 42

neutral

MACD trend Negative

52-week position 63%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +2%

trailing

6-month return +60%

trailing

YTD return +142%

this year

Relative strength +60%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $10 › 200d $7 — 50d above 200d

Institutional flow Accumulating

175 of 200 funds reported for Sep 30 · net +7.5M sh shares · +44 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

20.75% of shares out · ▼ -3.2% MoM · 9.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

200 holders — near 3-yr high, broad support

Squeeze score 76

high risk · 0–100

Fundamentals

Fair

Revenue growth −21%

Y/Y

EPS growth +11%

Y/Y

Free cash flow $-94.0M

Balance sheet $37.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 104%

annualized · 1-yr

Max drawdown −43%

past year

ATR 12.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+24% Bullish

Price vs 50-day avg

−12% Bearish

RSI (14)

42 Neutral

MACD trend

Negative Bearish

52-week position

63% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $10 › 200d $7 — 50d above 200d

Institutional flow Accumulating

175 of 200 funds reported for Sep 30 · net +7.5M sh shares · +44 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

20.75% of shares out · ▼ -3.2% MoM · 9.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

200 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $8 · 63% Range high $12

vs 200-day avg +24% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ABSI Absci Corp this stock	$1.46B	+142.1%	-20.7%	—	20.7%
VRTX Vertex Pharmaceuticals Inc	$136.56B	+18.8%	+46.2%	34.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$98.84B	+23.8%	+20.8%	21.1	2.1%
MRNA Moderna, Inc.	$90.38B	+657.4%	+4.3%	—	8.2%
CSLLY Csl Ltd	$66.05B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

227

% held: 93.6%
Reported: 175 of 200
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

166

View

Short & Settlement

Short Interest Falling

Shares short

35.8M

Days to cover: 9.1d
Change: -1.2M sh

View

Short Volume

Short vol %

49%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

45

Value: $435
As of: Oct 13, 2026

View

Off-Exchange

Off-exchange %

41.7%

Week of: Oct 5, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$4.5M

Net income (FY): $-115.2M
EPS diluted: $-0.84

View

Filings

SEC Filings

Latest

8-K

Filed: Nov 12, 2026
This year: 22

View

Proposed Sales

Value

$98.9K

Shares: 19.9K
Filed: Jun 13, 2024

View

Exempt Offerings

Offering

$125.0M

Filed: Mar 30, 2021

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 18, 2026

Last webcast: Nov 12, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
ABSI	-16.9%	+2.4%	+60.0%	-24.1%	+142.1%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-19.5%	+3.6%	+59.5%	-23.9%	+131.5%

ABSI · Absci Corp

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance